VA106483
Phase 1Small molecule
VA106483 is one of 20 small molecule programs targeting Hypertrophy. It is currently in Phase 1.
1
Indications
6
Total Trials
0
Active Trials
19
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
28 competitors in Hypertrophy
#DrugCompanyPhaseTrials
1Uroxatral
AAdvanz Pharma
Approved
Inspra
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Asmanex
NovartisPhase 3
Tylenol
KKenvue Brands
Approved
Ketalar
AAultman Health Foundation
Approved
Efanesoctocog Alfa
SanofiApproved
Precedex
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Approved
Cetrotide
EMD SeronoPhase 3
Ozempic
Novo NordiskPhase 2
Levitra
BayerPhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
1 more indication
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for VA106483. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company
- VVantia Ltd